Tests a lipid decision-support system for stroke patients taking evolocumab
Tests a computer tool guiding cholesterol treatment in adults after ischemic stroke or TIA.
Plain-language title generated from the registry record
Registry title: Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Beijing Tiantan HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07143149
- Record updated
- 2 January 2026
- Original description
This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.Read full original descriptionShow less
Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China
This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.
Inclusion: Age≥18 years as of the screening date; Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date; Prescribed Evolocumab at physician's discretion; Signed informed consent.
Exclusion: Participation in a clinical trial of another drug or device in the past 3 months or ongoing at the time of the screening date; Any prior use of Evolocumab or other PCSK9 inhibitor treatments within the past 6 months prior to the screening date; Intracranial hemorrhagic diseases: such as cerebral hemorrhage, subarachnoid hemorrhage, etc; Patients confirmed by baseline head CT or MRI to have hemorrhage or other pathological brain diseases, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis); Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders; Silent cerebral infarction without signs and symptoms; Life expectancy <12 months or unable to complete the research for other reasons as of the screening date; Refusal to participate in the enrollment survey.